FDA Approves SIR-Spheres for Unresectable HCC

The FDA approved yttrium-90 (Y-90) resin microspheres (SIR-Spheres, Sirtex Medical) for the treatment of unresectable hepatocellular carcinoma (HCC). 

Radioembolization, commonly referred to as selective internal radiation therapy, with SIR-Spheres uses personalized dosimetry to deliver the optimal dose of radiation directly to tumors in patients with HCC. This approval gives clinicians expanded flexibility in selecting a liver-directed therapy that aligns with patient-specific needs and